CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies
Press release content from Accesswire. The AP news staff was not involved in its creation. CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies February 2, 2021 GMT CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications CEVEC’s unique CAP(R) cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors The agreement supports CARISMA’s development of novel...
Source: apnews.com